Supernus Pharmaceuticals reported Q3 2020 total revenues of $155.1 million, including net product sales of $152.1 million. Operating earnings were $56.1 million, and net earnings were $40.0 million, or $0.74 per diluted share. The company increased its full-year 2020 net product sales guidance range to $500 million to $525 million and operating earnings guidance range to $145 million to $160 million.
Total revenues for Q3 2020 reached $155.1 million, with net product sales contributing $152.1 million and royalty revenues $3.0 million.
Operating earnings for Q3 2020 amounted to $56.1 million.
The company is preparing to launch SPN-812 in January 2021, pending FDA approval.
NDA for SPN-830 (Apomorphine infusion pump) was submitted to the FDA in September 2020.
Supernus Pharmaceuticals revised its full-year 2020 financial guidance, inclusive of the impact of acquiring the CNS portfolio of US WorldMeds.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance